New hope for stubborn lung cancer: combo therapy targets resistant tumors
NCT ID NCT07017829
First seen Jan 11, 2026 · Last updated Apr 29, 2026 · Updated 17 times
Summary
This study tests whether adding an experimental drug (GT103) to an existing immunotherapy (pembrolizumab) can help people with a specific type of advanced lung cancer (STK11 mutant NSCLC) that has stopped responding to treatment. About 28 adults whose cancer has spread will receive both drugs to see if the combination slows tumor growth. The goal is to improve outcomes for a cancer that is often resistant to standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Roswell Park Cancer Institute
RECRUITINGBuffalo, New York, 14263, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.